{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T03:01:34Z","timestamp":1773370894553,"version":"3.50.1"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Amgen Biotecnol\u00f3gica Colombia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s11657-021-00974-x","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T09:02:40Z","timestamp":1627117360000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Diagnostic, treatment, and follow-up of osteoporosis\u2014position statement of the Latin American Federation of Endocrinology"],"prefix":"10.1007","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5987-013X","authenticated-orcid":false,"given":"O.","family":"G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Talero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9397-1847","authenticated-orcid":false,"given":"M. B.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-2880","authenticated-orcid":false,"given":"M.","family":"Madeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9908-4907","authenticated-orcid":false,"given":"C. A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Campusano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Orjuela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cerdas P","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2581-134X","authenticated-orcid":false,"given":"M. P.","family":"de la Pe\u00f1a-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3732-8726","authenticated-orcid":false,"given":"A. A.","family":"Reza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Velazco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7898-9336","authenticated-orcid":false,"given":"B.","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. R.","family":"Uzc\u00e1tegui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8576-3645","authenticated-orcid":false,"given":"P. N.","family":"Rueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"key":"974_CR1","doi-asserted-by":"crossref","unstructured":"Aranco N, Stampini M, Ibarrar\u00e1n P, Medell\u00edn N (2018) Panorama de envejecimiento y dependencia en Am\u00e9rica Latina y el Caribe","DOI":"10.18235\/0000984"},{"key":"974_CR2","unstructured":"Comisi\u00f3n Econ\u00f3mica para Am\u00e9rica Latina y el Caribe (CEPAL) (2019) Anuario Estad\u00edstico de Am\u00e9rica Latina y el Caribe, 2018. Santiago"},{"issue":"3","key":"974_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00198-017-4341-4","volume":"29","author":"P Clark","year":"2018","unstructured":"Clark P, Denova-Guti\u00e9rrez E, Zerbini C, Sanchez A, Messina O, Jaller JJ et al (2018) FRAX-based intervention and assessment thresholds in seven Latin American countries. Osteoporos Int 29(3):707\u201315","journal-title":"Osteoporos Int"},{"issue":"2","key":"974_CR4","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00198-008-0657-4","volume":"20","author":"P Clark","year":"2009","unstructured":"Clark P, Cons-Molina F, Deleze M, Ragi S, Haddock L, Zanchetta JR et al (2009) The prevalence of radiographic vertebral fractures in Latin American countries: The Latin American Vertebral Osteoporosis Study (LAVOS). Osteoporos Int 20(2):275\u201382","journal-title":"Osteoporos Int"},{"key":"974_CR5","unstructured":"International Osteoporosis Foundation (2012) Latin America Regional Audit"},{"issue":"1","key":"974_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11657-019-0597-y","volume":"14","author":"DMW Silva","year":"2019","unstructured":"Silva DMW, Lazaretti-Castro M, Freitas Zerbini CA, de, Szejnfeld VL, Eis SR, Borba VZC. (2019) Incidence and excess mortality of hip fractures in a predominantly Caucasian population in the South of Brazil. Arch Osteoporos. 14(1):47","journal-title":"Arch Osteoporos."},{"key":"974_CR7","unstructured":"Ministerio de Salud P\u00fablica de Uruguay (2015) Decreto N\u00b0 38\/015"},{"issue":"1","key":"974_CR8","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s11657-018-0505-x","volume":"13","author":"B-H Albergaria","year":"2018","unstructured":"Albergaria B-H, Chalem M, Clark P, Messina OD, Pereira RMR, Vidal LF (2018) Consensus statement: osteoporosis prevention and treatment in Latin America\u2014current structure and future directions. Arch Osteoporos. 13(1):90","journal-title":"Arch Osteoporos."},{"key":"974_CR9","volume-title":"Health policies and systems in Latin America. En: Oxford Research Encyclopedia of Global Public Health","author":"AC Laurell","year":"2018","unstructured":"Laurell AC, Giovanella L (2018) Health policies and systems in Latin America. En: Oxford Research Encyclopedia of Global Public Health. Oxford University Press"},{"issue":"7","key":"974_CR10","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1080\/13696998.2019.1590843","volume":"22","author":"R Aziziyeh","year":"2019","unstructured":"Aziziyeh R, Amin M, Habib M, Garcia Perlaza J, Szafranski K, McTavish RK et al (2019) The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. J Med Econ 22(7):638\u201344","journal-title":"J Med Econ"},{"key":"974_CR11","unstructured":"FELAEN (2019) FELAEN \u2013 Federaci\u00f3n Latinoamericana de Endocrinolog\u00eda [Internet]. [citado 11 de diciembre de 2019]. Disponible en: https:\/\/felaen.org\/inicio\/"},{"key":"974_CR12","unstructured":"Grupo de Actualizaci\u00f3n de la Gu\u00eda Metodol\u00f3gica para el desarrollo de Gu\u00edas de Pr\u00e1ctica Cl\u00ednica, con Evaluaci\u00f3n Econ\u00f3mica en el SGSSS Colombiano (2014) Gu\u00eda Metodol\u00f3gica para la elaboraci\u00f3n de Gu\u00edas de Pr\u00e1ctica Cl\u00ednica con Evaluaci\u00f3n Econ\u00f3mica en el Sistema General de Seguridad Social en Salud Colombiano. Bogot\u00e1"},{"issue":"3","key":"974_CR13","doi-asserted-by":"publisher","first-page":"E123","DOI":"10.1503\/cmaj.131237","volume":"186","author":"HJ Schunemann","year":"2014","unstructured":"Schunemann HJ, Wiercioch W, Etxeandia I, Falavigna M, Santesso N, Mustafa R et al (2014) Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise. Can Med Assoc J 186(3):E123-42","journal-title":"Can Med Assoc J"},{"issue":"4","key":"974_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/ebmed-2016-110447","volume":"21","author":"BS Alper","year":"2016","unstructured":"Alper BS, Haynes RB (2016) EBHC pyramid 5.0 for accessing preappraised evidence and guidance. Evid Based Med 21(4):123\u20135","journal-title":"Evid Based Med"},{"key":"974_CR15","unstructured":"Scottish Intercollegiate Guidelines Network (SIGN) (2014) Critical appraisal: Notes and checklists [Internet]. [citado 21 de diciembre de 2019]. Disponible en: http:\/\/www.sign.ac.uk\/methodology\/checklists.html#"},{"issue":"1","key":"974_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/1471-2288-14-63","volume":"14","author":"K Grimmer","year":"2014","unstructured":"Grimmer K, Dizon JM, Milanese S, King E, Beaton K, Thorpe O et al (2014) Efficient clinical evaluation of guideline quality: development and testing of a new tool. BMC Med Res Methodol. 14(1):63","journal-title":"BMC Med Res Methodol."},{"issue":"1","key":"974_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/0142159X.2017.1245856","volume":"39","author":"S Humphrey-Murto","year":"2017","unstructured":"Humphrey-Murto S, Varpio L, Gonsalves C, Wood TJ (2017) Using consensus group methods such as Delphi and Nominal Group in medical education research. Med Teach 39(1):14\u20139","journal-title":"Med Teach"},{"key":"974_CR18","doi-asserted-by":"crossref","unstructured":"National Institute of Arthritis and Musculoskeletal and Skin Diseases, European Foundation for Osteoporosis and Bone Disease, American National Osteoporosis Foundation. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med. 1991;90(1):107\u201310.","DOI":"10.1016\/0002-9343(91)90512-V"},{"key":"974_CR19","doi-asserted-by":"crossref","unstructured":"European Foundation for Osteoporosis and Bone Disease, National Osteoporosis Foundation, National Institute of Arthritis and Musculoskeletal and Skin Diseases. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993;94(6):646\u201350.","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"974_CR20","unstructured":"National Institute for Health and Clinical Excellence (NICE). Osteoporosis: Assessing the risk of fragility fracture. 2012."},{"key":"974_CR21","unstructured":"Royal Australian College of General Practitioners, Osteoporosis Australia. Osteoporosis prevention, diagnosis and management in postmenopausal women and men over 50 years of age, 2nd edition. 2017."},{"key":"974_CR22","doi-asserted-by":"crossref","unstructured":"Naves D\u00edaz M, Bernardino D\u00edaz L\u00f3pez J, G\u00d3mez Alonso C, Altadill Arregui A, Rodr\u00edguez Rebollar A, B. Cannata And\u00eda J. Estudio de incidencia de fracturas osteopor\u00f3ticas en una cohorte mayor de 50 a\u00f1os durante un per\u00edodo de 6 a\u00f1os de seguimiento. Med Clin (Barc). 2000;115(17):650\u20133.","DOI":"10.1016\/S0025-7753(00)71651-4"},{"issue":"4","key":"974_CR23","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","volume":"27","author":"CM Weaver","year":"2016","unstructured":"Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R et al (2016) The National Osteoporosis Foundation\u2019s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 27(4):1281\u2013386","journal-title":"Osteoporos Int."},{"issue":"Supplement 4","key":"974_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP161435.GL","volume":"22","author":"PM Camacho","year":"2016","unstructured":"Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment. Endocr Pract. 22(Supplement 4):1\u201342","journal-title":"Endocr Pract."},{"key":"974_CR25","unstructured":"Mendoza B, Ronco \u00c1L. Estacionalidad de la vitamina D plasm\u00e1tica: su importancia en la cl\u00ednica y en la salud . Vol. 32, Revista M\u00e9dica del Uruguay . scielouy ; 2016. p. 80\u20136."},{"issue":"1","key":"974_CR26","doi-asserted-by":"publisher","first-page":"e1248325","DOI":"10.1080\/19381980.2016.1248325","volume":"8","author":"DG Hoel","year":"2016","unstructured":"Hoel DG, Berwick M, de Gruijl FR, Holick MF (2016) The risks and benefits of sun exposure 2016. Dermatoendocrinology 8(1):e1248325","journal-title":"Dermatoendocrinology"},{"issue":"6","key":"974_CR27","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41370-019-0137-2","volume":"29","author":"A Religi","year":"2019","unstructured":"Religi A, Backes C, Chatelan A, Bulliard J-L, Vuilleumier L, Moccozet L et al (2019) Estimation of exposure durations for vitamin D production and sunburn risk in Switzerland. J Expo Sci Environ Epidemiol. 29(6):742\u201352","journal-title":"J Expo Sci Environ Epidemiol."},{"key":"974_CR28","unstructured":"Lewiecki EM. Osteoporosis: Clinical Evaluation. En: Feingold K, Anawalt B, Boyce A, editores. Endotext. South Darthmouth: MDText.com, Inc.; 2000."},{"issue":"8","key":"974_CR29","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650090802","volume":"9","author":"JA Kanis","year":"1994","unstructured":"Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res. 9(8):1137\u201341","journal-title":"J Bone Miner Res."},{"issue":"5","key":"974_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4158\/GL-2020-0524","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update. Endocr Pract 26(5):564\u2013570","journal-title":"Endocr Pract"},{"issue":"1","key":"974_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.4158\/EP12059.RA","volume":"19","author":"S Hudec","year":"2013","unstructured":"Hudec S, Camacho P (2013) Secondary Causes of Osteoporosis. Endocr Pract 19(1):120\u2013128","journal-title":"Endocr Pract"},{"issue":"7041","key":"974_CR32","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 312(7041):1254\u20139","journal-title":"BMJ."},{"key":"974_CR33","doi-asserted-by":"crossref","unstructured":"Dhiman P, Andersen S, Vestergaard P, Masud T, Qureshi N. Does bonemineral density improve the predictive accuracy of fracture risk assessment?A prospective cohort study in Northern Denmark. BMJ Open. 2018;8(4):e018898.","DOI":"10.1136\/bmjopen-2017-018898"},{"key":"974_CR34","unstructured":"The International Society for Clinical Densitometry (ISCD). 2019 ISCD Official Positions Adult [Internet]. 2019 [citado 18 de mayo de 2020]. Disponible en: https:\/\/iscd.app.box.com\/s\/5r713cfzvf4gr28q7zdccg2i7169fv86."},{"key":"974_CR35","doi-asserted-by":"crossref","unstructured":"Borges JLC, Sousa da Silva M, Ward RJ, Diemer KM, Yeap SS, Lewiecki EM. Repeating Vertebral Fracture Assessment: 2019 ISCD Official Position. J Clin Densitom. 2019;22(4):484\u20138.","DOI":"10.1016\/j.jocd.2019.07.005"},{"issue":"4","key":"974_CR36","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jocd.2013.08.003","volume":"16","author":"HN Rosen","year":"2013","unstructured":"Rosen HN, Vokes TJ, Malabanan AO, Deal CL, Alele JD, Olenginski TP et al (2013) The Official Positions of the International Society for Clinical Densitometry: Vertebral Fracture Assessment. J Clin Densitom 16(4):482\u2013488","journal-title":"J Clin Densitom"},{"issue":"3","key":"974_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jocd.2015.06.008","volume":"18","author":"BC Silva","year":"2015","unstructured":"Silva BC, Broy SB, Boutroy S, Schousboe JT, Shepherd JA, Leslie WD (2015) Fracture Risk Prediction by Non-BMD DXA Measures: the 2015 ISCD Official Positions Part 2: Trabecular Bone Score. J Clin Densitom 18(3):309\u2013330","journal-title":"J Clin Densitom"},{"issue":"7","key":"974_CR38","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/jbmr.3124","volume":"32","author":"P Martineau","year":"2017","unstructured":"Martineau P, Leslie WD, Johansson H, Oden A, McCloskey EV, Hans D et al (2017) Clinical Utility of Using Lumbar Spine Trabecular Bone Score to Adjust Fracture Probability: The Manitoba BMD Cohort. J Bone Miner Res 32(7):1568\u20131574","journal-title":"J Bone Miner Res"},{"key":"974_CR39","doi-asserted-by":"publisher","first-page":"115297","DOI":"10.1016\/j.bone.2020.115297","volume":"134","author":"G Adami","year":"2020","unstructured":"Adami G, Arioli G, Bianchi G, Brandi ML, Caffarelli C, Cianferotti L et al (2020) Radiofrequency echographic multi spectrometry for the prediction of incident fragility fractures: A 5-year follow-up study. Bone. 134:115297","journal-title":"Bone."},{"issue":"2","key":"974_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-018-4686-3","volume":"30","author":"M Di Paola","year":"2019","unstructured":"Di Paola M, Gatti D, Viapiana O, Cianferotti L, Cavalli L, Caffarelli C et al (2019) Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. Osteoporos Int. 30(2):391\u2013402","journal-title":"Osteoporos Int."},{"key":"974_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.measurement.2016.01.033","volume":"101","author":"A Greco","year":"2017","unstructured":"Greco A, Pisani P, Conversano F, Soloperto G, Renna MD, Muratore M et al (2017) Ultrasound Fragility Score: An innovative approach for the assessment of bone fragility. Measurement 101:236\u2013242","journal-title":"Measurement"},{"issue":"10","key":"974_CR42","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s40520-019-01294-4","volume":"31","author":"A Diez-Perez","year":"2019","unstructured":"Diez-Perez A, Brandi ML, Al-Daghri N, Branco JC, Bruy\u00e8re O, Cavalli L et al (2019) Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art\u2014outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Mus. Aging Clin Exp Res. 31(10):1375\u201389","journal-title":"Aging Clin Exp Res."},{"issue":"10122","key":"974_CR43","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R et al (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391(10122):741\u2013747","journal-title":"Lancet"},{"issue":"2","key":"974_CR44","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/MOG.0b013e32835004dc","volume":"28","author":"P Pramyothin","year":"2012","unstructured":"Pramyothin P, Holick MF (2012) Vitamin D supplementation. Curr Opin Gastroenterol 28(2):139\u2013150","journal-title":"Curr Opin Gastroenterol"},{"issue":"4","key":"974_CR45","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1210\/jc.2011-2218","volume":"97","author":"CJ Rosen","year":"2012","unstructured":"Rosen CJ, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA et al (2012) IOM Committee Members Respond to Endocrine Society Vitamin D Guideline. J Clin Endocrinol Metab 97(4):1146\u20131152","journal-title":"J Clin Endocrinol Metab"},{"key":"974_CR46","doi-asserted-by":"crossref","unstructured":"Aguiar Moreira C, dos S. Ferreira C, Madeira M, Carvalho Silva B, Setsuo Maeda S, Cidade Batista M, et al. Reference values of 25-hydroxyvitamin D revisited: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Society of Clinical Pathology\/ Laboratory Medicine (SBPC). Arch Endocrinol Metab. 2020;1\u201317.","DOI":"10.20945\/2359-3997000000258"},{"issue":"7","key":"974_CR47","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","volume":"96","author":"MF Holick","year":"2011","unstructured":"Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP et al (2011) Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96(7):1911\u20131930","journal-title":"J Clin Endocrinol Metab"},{"key":"974_CR48","unstructured":"Institute of Medicine, Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary Reference Intakes for Calcium and Vitamin D. Ross A, Taylor C, Yaktine A, editores. Washington, D.C.: National Academies Press; 2011."},{"key":"974_CR49","doi-asserted-by":"crossref","unstructured":"Avenell A, Mak JC, O\u2019Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database Syst Rev. 2014.","DOI":"10.1002\/14651858.CD000227.pub4"},{"issue":"15","key":"974_CR50","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2017.21640","volume":"319","author":"LC Kahwati","year":"2018","unstructured":"Kahwati LC, Weber RP, Pan H, Gourlay M, LeBlanc E, Coker-Schwimmer M et al (2018) Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults. JAMA. 319(15):1600","journal-title":"JAMA."},{"key":"974_CR51","doi-asserted-by":"crossref","unstructured":"Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline. JAMA Intern Med. 2016;176(2):175","DOI":"10.1001\/jamainternmed.2015.7148"},{"issue":"5","key":"974_CR52","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 104(5):1595\u2013622","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"974_CR53","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1007\/s00198-016-3654-z","volume":"27","author":"J Zhou","year":"2016","unstructured":"Zhou J, Ma X, Wang T, Zhai S (2016) Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 27(11):3289\u2013300","journal-title":"Osteoporos Int."},{"key":"974_CR54","unstructured":"DynaMed. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T113815, Osteoporosis [Internet]. 2018 [citado 29 de enero de 2020]. Disponible en: https:\/\/www.dynamed.com\/topics\/dmp~AN~T113815. Registration and login required."},{"issue":"5","key":"974_CR55","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2019-00192","volume":"104","author":"P Barrionuevo","year":"2019","unstructured":"Barrionuevo P, Kapoor E, Asi N, Alahdab F, Mohammed K, Benkhadra K et al (2019) Efficacy of pharmacological therapies for the prevention of fractures in postmenopausal women: a network meta-analysis. J Clin Endocrinol Metab. 104(5):1623\u201330","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"974_CR56","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 5(7):513\u2013523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"974_CR57","doi-asserted-by":"crossref","unstructured":"Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen J-EB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190\u20138.","DOI":"10.1002\/jbmr.3337"},{"key":"974_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2018.09.020","volume":"120","author":"A D\u00edez-P\u00e9rez","year":"2019","unstructured":"D\u00edez-P\u00e9rez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodr\u00edguez M (2019) Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: a systematic review and meta-analysis. Bone 120:1\u20138","journal-title":"Bone"},{"issue":"4","key":"974_CR59","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1359\/jbmr.081215","volume":"24","author":"R Eastell","year":"2009","unstructured":"Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J et al (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)*. J Bone Miner Res 24(4):726\u2013736","journal-title":"J Bone Miner Res"},{"issue":"6","key":"974_CR60","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1080\/03007995.2018.1552576","volume":"35","author":"C-H Chen","year":"2019","unstructured":"Chen C-H, Elsalmawy AH, Ish-Shalom S, Lim S-J, Al-Ali NS, Cunha-Borges JL et al (2019) Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS). Curr Med Res Opin. 35(6):1041\u20139","journal-title":"Curr Med Res Opin."},{"key":"974_CR61","doi-asserted-by":"publisher","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","volume":"130","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Martyn-St James M, Hamilton J, Wong R, Gittoes N, Selby P et al (2020) Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: a systematic review and network meta-analysis. Bone. 130:115081","journal-title":"Bone."},{"issue":"2","key":"974_CR62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/13697137.2018.1433655","volume":"21","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Y, Zhang S, Zhang W, Zhang B, Tang Q et al (2018) Romosozumab treatment in postmenopausal women with osteoporosis: a meta-analysis of randomized controlled trials. Climacteric. 21(2):189\u201395","journal-title":"Climacteric."},{"key":"974_CR63","unstructured":"Food and Drugs Administration - FDA. Highlights of prescribing information - Evenity [Internet]. 2019 [citado 30 de mayo de 2020]. Disponible en: www.fda.gov\/medwatch."},{"issue":"13","key":"974_CR64","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1056\/NEJMoa1505241","volume":"374","author":"HN Hodis","year":"2016","unstructured":"Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J et al (2016) Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 374(13):1221\u201331","journal-title":"N Engl J Med."},{"key":"974_CR65","doi-asserted-by":"crossref","unstructured":"Sanchez-Rodriguez D, Bergmann P, Body JJ, Cavalier E, Gielen E, Goemaere S, et al. The Belgian Bone Club 2020 guidelines for the management of osteoporosis in postmenopausal women. Maturitas. 2020.","DOI":"10.1016\/j.maturitas.2020.05.006"},{"issue":"1","key":"974_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 30(1):3\u201344","journal-title":"Osteoporos Int."},{"key":"974_CR67","doi-asserted-by":"publisher","first-page":"100216","DOI":"10.1016\/j.bonr.2019.100216","volume":"11","author":"F Al Anouti","year":"2019","unstructured":"Al Anouti F, Taha Z, Shamim S, Khalaf K, Al Kaabi L, Alsafar H (2019) An insight into the paradigms of osteoporosis: from genetics to biomechanics. Bone Reports. 11:100216","journal-title":"Bone Reports."},{"key":"974_CR68","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.cca.2019.08.012","volume":"498","author":"Y Nishizawa","year":"2019","unstructured":"Nishizawa Y, Miura M, Ichimura S, Inaba M, Imanishi Y, Shiraki M et al (2019) Executive summary of the Japan Osteoporosis Society Guide for the Use of Bone Turnover Markers in the Diagnosis and Treatment of Osteoporosis (2018 Edition). Clin Chim Acta 498:101\u20137","journal-title":"Clin Chim Acta"},{"issue":"10","key":"974_CR69","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1007\/s12325-019-01063-9","volume":"36","author":"M Lorentzon","year":"2019","unstructured":"Lorentzon M, Branco J, Brandi ML, Bruy\u00e8re O, Chapurlat R, Cooper C et al (2019) Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 36(10):2811\u201324","journal-title":"Adv Ther."},{"key":"974_CR70","unstructured":"Wu C-H, Chang Y-F, Chen C-H, Lewiecki EM, W\u00fcster C, Reid I, et al. Consensus statement on the use of bone turnover markers for short-term monitoring of osteoporosis treatment in the Asia-Pacific Region. J Clin Densitom. 2019."},{"key":"974_CR71","doi-asserted-by":"crossref","unstructured":"Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab. 2020;105(3).","DOI":"10.1210\/clinem\/dgaa048"},{"key":"974_CR72","unstructured":"European Medicines Agency - EMA. Summary of product characteristics - Terrosa. 2017."},{"key":"974_CR73","unstructured":"Food and Drugs Administration - FDA. Highlights of prescribing information - Bonsity. 2019."},{"key":"974_CR74","unstructured":"ClinicalTrials.gov. Study Investigating PK, PD, Efficacy, safety, and immunogenicity of biosimilar denosumab (GP2411) in patients with postmenopausal osteoporosis [Internet]. 2019 [citado 4 de junio de 2020]. Disponible en: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03974100"},{"issue":"1","key":"974_CR75","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13696998.2020.1864920","volume":"24","author":"R Aziziyeh","year":"2021","unstructured":"Aziziyeh R, Perlaza JG, Saleem N, Guiang H, Szafranski K, McTavish RK (2021) Benefits of fracture liaison services (FLS) in four Latin American countries: Brazil, Mexico, Colombia, and Argentina. J Med Econ 24(1):96\u2013102","journal-title":"J Med Econ"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00974-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-021-00974-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-021-00974-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T07:28:43Z","timestamp":1666769323000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-021-00974-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["974"],"URL":"https:\/\/doi.org\/10.1007\/s11657-021-00974-x","relation":{},"ISSN":["1862-3522","1862-3514"],"issn-type":[{"value":"1862-3522","type":"print"},{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"10 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"<i>PNR<\/i> has received support from Lilly for an academic event and has been a speaker for Lilly and Sanulac. <i>APT<\/i> assisted to academic events with the support of Amgen and Novo Nordisk and has received lecture fees from MSD. <i>MBZ<\/i> has been sponsored in an academic event by Amgen; has been a speaker for Lilly, Takeda, and Amgen; and received a grant from Ultragenyx. <i>MM<\/i> assisted to academic events with the support of Amgen and Ach\u00e9 and has received research grants from Shire and Alexion. <i>CAM<\/i> attended academic events with support from Amgen and Ultragenyx and has received research and academic grants from Ultragenyx. <i>CC<\/i> received support for an academic event and has received lecture fees from Tecnofarma and was previously employed as Medical Director at Cl\u00ednica Universidad de Los Andes. <i>AMO<\/i> attended an academic event sponsored by Amgen and has received lecture fees from Lilly, Amgen, and Farma. <i>SC<\/i> has received support from MD Pharma, Janssen Cilag, Asofarma, and Pfizer and has been a speaker for Asofarma and MD Pharma. <i>PDP<\/i> has been a speaker in academic events for Lilly and Amgen and received research grants from Lilly. <i>AARA<\/i> assisted to an academic event with the support of Merck. <i>CV<\/i> attended academic events supported by Lilly, Grupo Mallen, and Asofarma; has been a speaker for Asofarma, Lilly, and Novartis; and received research grants from Novartis and Astellas. <i>BM<\/i> received support for attending academic events from Gador and research grants from Urufarma. <i>LRUO<\/i> has nothing to declare. <i>OG<\/i> attended academic events with the support of GSK and Roche and consults for Pharmalab.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"114"}}